Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_6036_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •1: MOSS: A Patient-Centered Approach
- •Background
- •Historical Approaches
- •Medical/Mental Component
- •Oncologic Component
- •Stenosis (Ambulatory/Neurologic) Component
- •Stability Component
- •Summary
- •Application of MOSS: Three Case Reports
- •Case 1
- •Case 2
- •MOSS, A Patient-Centered Approach to Metastatic Disease of the Spine
- •Case 3
- •References
- •2: Relative Radiosensitivity of Metastatic Spine Disease
- •References
- •3: Relative Chemo-, Hormonal, and Immunosensitivity
- •Introduction
- •Assessing Response to Treatment
- •Tissue Procurement
- •Variability of Sensitivity
- •Breast Cancer
- •Lung Cancer
- •Prostate Cancer
- •Renal Cell Carcinoma
- •Lymphoma
- •Myeloma
- •Sarcoma
- •Bone Antiresorptive Therapy
- •References
- •4: NOMS
- •NOMS Framework
- •Neurologic
- •Oncologic
- •Radiation
- •Mechanical
- •Systemic
- •Surgical Considerations
- •Separation Surgery
- •Surgical Stabilization
- •Case Illustrations
- •References
- •Introduction
- •Initial Evaluation
- •Clinical Evaluation
- •Radiographic Evaluation
- •Plain Radiographs
- •Nuclear Medicine Scans
- •Computed Tomography
- •Magnetic Resonance
- •Denis
- •Taneichi
- •Asdourian
- •SINS
- •References
- •6: Imaging Metastatic Spinal Disease
- •Background
- •Imaging Considerations
- •Radiography
- •Computed Tomography
- •Magnetic Resonance Imaging
- •Bone Scintigraphy
- •Positron-Emission Tomography
- •Approach to Evaluating the Spine
- •Illustrative Cases in Diagnostic Imaging
- •Case 1
- •Case 2
- •Case 3
- •Case 4
- •Case 5
- •Case 6
- •Case 7
- •Case 8
- •Case 9
- •References
- •7: Management of Metastatic Spinal Cord Compression Without Stereotactic Radiotherapy and Targeted Adjuvant Chemotherapy
- •Introduction
- •Role of Spine Surgery in Metastatic Spinal Cord Compression Treatment
- •The Role of Minimally Invasive (MI) Techniques in MESCC
- •Decision-Making in Case of Metastatic Spinal Cord Compression
- •Flow Chart for Multidisciplinary Management of Metastases in the Mobile Spine
- •Experience at Our Institution
- •Materials and Methods
- •Results
- •References
- •8: Metastatic Spine Disease: Critical Evaluation of the Current Literature
- •Introduction
- •Steroids
- •Radiotherapy
- •Background
- •Indications
- •Stereotactic Radiosurgery
- •Surgery
- •Treatment Framework
- •References
- •9: Indications for En Bloc Spondylectomy for Metastatic Spine Disease
- •Surgical Considerations
- •Outcomes
- •References
- •10: Occipitocervical and Upper Cervical Metastatic Spinal Disease
- •Introduction
- •Epidemiology
- •Presentation
- •Diagnostic Workup
- •Laboratory Studies
- •Treatment Strategy
- •Radiation
- •Surgery
- •References
- •11: Mid-cervical Metastatic Spinal Disease
- •Epidemiology
- •Pathology
- •Clinical Presentation
- •Diagnosis
- •Surgical Approaches
- •Anterior
- •Posterior
- •Complication Avoidance
- •References
- •12: Cervicothoracic Metastatic Spine Disease
- •General Spinal Metastasis
- •Patient Presentation
- •Evaluation, Imaging, and Work-Up
- •General Indications for Surgery
- •Surgical Goals and Approaches
- •Cervical Spine
- •Thoracic Spine
- •Tumor Resection Strategies and Extent of Resection
- •Surgical Complications
- •References
- •13: Surgical Treatment for Patients with Thoracic Spinal Metastasis
- •Introduction
- •Preoperative Planning
- •Identify the Problem
- •Establish Reasonable Goals
- •Select an Approach
- •Establish the Surgical Plan and a Backup Plan
- •Optimize the Patient
- •Surgical Techniques
- •Biopsy Technique
- •Fine Needle Aspiration Biopsy
- •Core Needle or Trephine Biopsy
- •Posterolateral Decompression and Fusion in the Upper Thoracic Spine
- •Surgical Techniques
- •MIS Fixation Techniques
- •Separation Surgery
- •Mid-thoracic Metastases: Combined Anterior and Posterior Reconstruction
- •Reconstruction of the Thoracic Spine
- •Posterior Instrumentation
- •Anterior Reconstruction
- •MIS Techniques for the Lower Thoracic and Thoracolumbar Spine
- •Vertebroplasty and Kyphoplasty
- •References
- •14: Thoracolumbar Metastatic Spinal Disease
- •Introduction
- •Anterolateral Corridor Techniques
- •Anterolateral Corridor Obstacles
- •Patient Selection
- •Surgical Approaches: Localization
- •Planning the Surgical Incision
- •Open Thoracoabdominal Approach (Retroperitoneal, Intrathoracic)
- •Intrathoracic Portion
- •Retroperitoneal Portion
- •Extracoelomic Approach Technique
- •Chest Tube Placement
- •Red Rubber Catheter Technique for Evacuation of Retropleural Air
- •Minimal Access Lateral Corpectomy Approach
- •Approach
- •Minimally Invasive Surgical Approaches
- •Positioning
- •Optimizing Fluoroscopic Imaging
- •Retractor Placement
- •Corpectomy and Tumor Resection
- •Exposure of T12
- •Exposure of L1
- •Discectomies
- •T12 Corpectomy
- •Place Anterior Column Support With or Without Side Plate and Screw Instrumentation
- •Posterior Pedicle Screw Fixation
- •References
- •Introduction
- •Indications
- •Biomechanics
- •Cervicothoracic Junction Approaches
- •Low Anterior Approach
- •Sternal-Splitting Approaches
- •Reconstruction Techniques
- •Complications
- •Thoracic/Thoracolumbar Approaches
- •Transthoracic Approach (T3-T11)
- •Corpectomy Technique
- •Thoracoabdominal Transdiaphragmatic Approach (T10–L2)
- •Reconstruction Techniques
- •Complications
- •Lumbar Approaches
- •Anterior Retroperitoneal Approach
- •Transperitoneal Approach
- •Lateral Flank Retroperitoneal Approach
- •Reconstruction Techniques
- •Complications
- •References
- •Introduction
- •Anatomy
- •Clinical Presentation
- •Imaging
- •Workup
- •Treatment Strategy
- •Nonoperative Treatment
- •Corticosteroids
- •Chemotherapy
- •Radiotherapy
- •Operative Treatment
- •Neural Compression
- •Instability
- •Local Control
- •Pain
- •References
- •17: Vertebral Body Reconstruction in Metastatic Spine Disease
- •Introduction
- •Fixation
- •Augmentation
- •Surgical Selection
- •Radiographic Studies
- •Preoperative Diagnosis
- •Presurgical Planning and Approach
- •Positioning
- •Reconstruction of the Vertebral Body
- •Technical Considerations
- •Discussion
- •References
- •18: Lumbosacral Metastatic Spine Disease
- •Introduction
- •Lumbopelvic Bony Anatomy and Biomechanics
- •Neurovascular Anatomy
- •Surgical Indications and Preoperative Management
- •Resection Considerations
- •Anterior Approach
- •Posterior Approach
- •Reconstruction and Stabilization
- •Authors’ Preferred Technique for Resection and Reconstruction
- •Postoperative Care
- •References
- •19: Sacral Metastases
- •Introduction
- •Anatomy of the Sacrum
- •Clinical and Diagnostic Features
- •Imaging and Biopsy
- •Management of Sacral Metastasis
- •References
- •20: Radiation Therapy for Spinal Metastases
- •References
- •21: Reconstructive Flap Coverage
- •Background
- •Principles of Flap Coverage
- •Surgical Timing and Risk Factors for Wound Complications
- •Strategies for Delayed Management of Complex Spine Wounds
- •Regional Approach to Flap Selection
- •Summary
- •References
- •22: Complications
- •Introduction
- •Preoperative Planning
- •Biopsy
- •Surgical Decision-Making and Approach
- •Positioning
- •Appropriate Level and Side
- •Complications
- •Neurological Complications
- •Dural Tears
- •Complications Associated with Spinal Instrumentation
- •Visceral Injury
- •Pulmonary Complications
- •Genitourinary Complications
- •Dysphagia and Hoarseness
- •Ileus/Gastrointestinal
- •Vascular
- •Thoracic Duct Injury
- •Thromboembolic Disease
- •Infection
- •Wound Complications
- •Radiation-Associated
- •Complications Associated with Corticosteroid Utilization
- •Deformity
- •Fluid and Electrolyte Imbalance
- •References
- •23: Percutaneous Thermal Ablation of Spine Metastasis
- •Background
- •Fundamental Concepts
- •Procedural Technique
- •Risks and Limitations
- •References
- •24: Minimally Invasive Spine Surgery for Metastatic Spine Disease
- •Introduction
- •Survival
- •Quality of Life
- •Adjuvant Therapy
- •Vertebral Augmentation with Cement
- •Posterior Percutaneous Stabilization
- •Minimally Invasive Decompression
- •Case Example No. 1
- •References
- •Index

3 Relative Chemo-, Hormonal, and Immunosensitivity
35
First-line therapy consists of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone
followed by the monoclonal antibody rituximab)
[54]. Response rates vary from 65% complete
response (CR) in secondary lymphoma of bone
(Stage IV) to 95% CR in primary lymphoma of
bone (Stage IE or IIE) [55]. Given the substantial
sensitivity of DLBCL of bone to chemotherapy,
immunotherapy, steroids, and radiation, surgical
management is rarely indicated outside of biopsy
or stabilization of an acutely unstable bony lesion.
An additional surgical indication is decompression
of high-grade epidural compression; however, in
contrast to the results in metastatic carcinoma, it is
not clear that the functional outcomes in lymphoma
are superior with decompression surgery versus
chemotherapy and radiation [56].
Myeloma
The present discussion will focus on active
multiple myeloma, exclusive of solitary plasmacytoma, smoldering multiple myeloma, and
monoclonal gammopathy of undetermined signicance—disease entities for which systemic
treatment is not routinely indicated. The mainstay
of systemic therapy for active myeloma consists
of induction chemotherapy with agents such as
bortezomib, thalidomide/lenalidomide, and corticosteroids, followed by hematopoietic cell transplantation (HCT) in eligible candidates. Patients
who are ineligible for HCT receive maintenance
chemotherapy [57].
The choice of therapy and anticipated sensitivity or time to progression are inuenced by
risk stratication models that are based on FISH
analysis of known translocations, gene expression proles, serum lactate dehydrogenase levels,
and response to prior therapy [58]. Patients typically demonstrate good sensitivity to the above
therapy regimens initially, but those with highrisk proles can experience disease progression
in 8–18months, as compared with 25–36months
for standard-risk myeloma patients [59, 60].
Other predictors of early disease progression on
therapy (and, by association, shorter overall survival) include age >65years, albumin <3 g/dL,
serum β2 microglobulin >4mg/dL, hemoglobin
<10g/dL, platelets <150/mm3, and involvement
of more than three bones [61].
Sarcoma
Metastatic sarcomatous lesions of the spine are
relatively infrequent, and their systemic and local
management is controversial. However, myxoid
liposarcoma does show a predilection for metastasis to the spine and, therefore, warrants a discussion in this context. Spine metastases are present
in 8–14% of patients with myxoid liposarcoma
and in 82–83% of those with bone metastases [62,
63]. Screening is most appropriately performed
with MRI [64]. Treatment is usually palliative,
though reports of long-term control with en bloc
excision exist [65]. Compared to other liposarcoma subtypes, myxoid liposarcoma is relatively
chemosensitive to conventional regimens, including doxorubicin with or without ifosfamide, with
a partial response rate of 48%. The PFS is short,
though, at a median of 4months [66]. A promising second line of therapy has been reported with
trabectedin, which demonstrates specic efcacy
against translocation-associated sarcomas and
has been shown to produce a PFS of 7.3months
in myxoid liposarcomas that were unresponsive
to doxorubicin therapy [67].
Bone Antiresorptive Therapy
A discussion of metastatic disease of the spine
would not be complete without inclusion of bone
antiresorptive therapy, namely, bisphosphonates
and denosumab. The relevant indications for initiating these medications include (1) minimizing
vertebral fragility fracture risk due to treatmentrelated decline in bone mineral density (BMD),
(2) lowering the rate of skeletal-related events
(SRE) from metastatic spine lesions, and (3)
potentially reducing disease recurrence.
Antineoplastic therapy can contribute to bone
loss via alterations of hormonal balance (e.g.,
aromatase inhibitors in breast cancer or LHRH in
prostate cancer) [68, 69], administration of

36
Rates of bone loss in men and women
81
% Bone loss at 1 year
Fig. 3.3 One-year rates of bone loss in men and
women are shown. Bone loss while receiving cancer therapy [68–72] tends to occur at a higher rate
than bone loss associated with normal aging [74].
GnRH, gonadotropin- releasing hormone
M. Vaynrub and J. H. Healey
with and without cancer therapy
Normal men 0.5
Postmenopausal women
(age >55 years)
1.0
Associated
with
normal
aging
exogenous corticosteroids (e.g., prednisone in
lymphoma), bone marrow transplantation [70],
and/or chemotherapy-induced ovarian failure
(common to many chemotherapy regimens) [71,
72]. The effect of chemotherapy-induced prema-
ture menopause may be the most potent, resulting
in a 7.7% reduction in vertebral BMD after 1year
compared to a 2.0% decline with normal menopause [71, 73, 74] (Fig. 3.3). Interestingly,
tamoxifen can have a protective effect on BMD
in postmenopausal patients but a paradoxical deleterious effect on BMD in patients who remain
premenopausal [75]. Denosumab 60mg subcutaneously every 6months carries FDA approval for
treatment-related bone loss [76], and bisphosphonates also have proven efcacy for this indication [77, 78]. In contrast, teriparatide is
generally avoided in patients with bone malignancy or a history of radiation to the bone, due to
a theoretical increased risk of secondary osteosarcoma [79].
Antiresorptive therapy is fundamental to
decreasing pain, improving quality of life, and
preventing or delaying the time to skeletal-related
events (SRE) in patients with established metastatic disease of the spine [80, 81]. SRE in this
context includes pain requiring surgical or radio-
Menopausal women
(age <55 years)
Aromatase inhibitor therapy
in postmenopausal women
Bone marrow
transplantation
Androgen deprivation therapy
+ GnRH agonist in men
Aromatase inhibitor therapy
secondary to chemotherapy
+ GnRH agonist
in premenopausal women
Premature menopause
2.0
2.3
3.3
4.6
0 246
Associated
with
cancer
therapy
7.4
7.7
0
therapy intervention, vertebral pathologic compression fracture, or spinal cord compression.
Denosumab 120 mg subcutaneously every
4 weeks and zoledronic acid 4 mg intravenous
infusion every 3–4weeks are both FDA-approved
for prevention of SRE in bone metastases from
solid tumors (and myeloma in the case of zoledronic acid) [82, 83]. Denosumab has shown
superiority to bisphosphonates in this regard in
breast cancer and prostate cancer [84, 85].
Noninferiority of denosumab compared with
zoledronic acid was demonstrated for bony
metastases from other solid tumors as well as
multiple myeloma [86].
In addition to their benecial effects on BMD
and SRE, there is evidence that antiresorptive
medications have antitumor antimetastatic activity. In vitro and animal studies have shown a
pro- apoptotic effect as well as alteration of the
interaction of disseminated tumor cells with
the bone microenvironment [73]. The most
compelling evidence is in breast cancer studies, as a recent meta-analysis has indicated that
postmenopausal breast cancer patients taking
bisphosphonates seem to demonstrate improved
overall survival and disease-free survival as compared with controls [87].

3 Relative Chemo-, Hormonal, and Immunosensitivity
37
Conclusion
Systemic management options factor heavily
into surgical decision-making for metastatic
disease of the spine. A systematic approach
starts with selection of appropriate biopsy
timing, anatomic location, method, and
approach. A comprehensive histologic and
molecular analysis will allow an informed
consultation with the medical oncologist
regarding anticipated response rate, timeline,
and durability, as well as expected patient survival. Malignancies with poor responses to
systemic therapy may require more aggressive
surgical or radiation intervention, while those
with reliable and rapid responses may not
require any invasive intervention. Patients
with longer life expectancies may require
more durable reconstruction, while the emphasis may shift to minimizing surgical morbidity
and the postoperative recovery timeline in
those with limited remaining life expectancy.
The implications of proposed systemic therapy on bone mineral density require consideration of bone-reinforcing medications to
minimize the risk of insufciency fractures.
Once equipped with this knowledge, the spine
surgeon can truly develop the best palliative
decisions with the patient.
References
1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH,
Sargent D, Ford R, etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
2. Vassiliou V, Andreopoulos D, Frangos S, Tselis N,
Giannopoulou E, Lutz S. Bone metastases: assessment of therapeutic response through radiological and
nuclear medicine imaging modalities. Clin Oncol (R
Coll Radiol). 2011;23(9):632–45.
3. Vogel CL, Schoenfelder J, Shemano I, Hayes DF,
Gams RA.Worsening bone scan in the evaluation of
antitumor response during hormonal therapy of breast
cancer. J Clin Oncol. 1995;13(5):1123–8.
4. Coleman RE, Mashiter G, Whitaker KB, Moss DW,
Rubens RD, Fogelman I.Bone scan are predicts successful systemic therapy for bone metastases. J Nucl
Med. 1988;29(8):1354–9.
5. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry
DA, Islam R, et al. Tumour response interpretation
with new tumour response criteria vs the World Health
Organisation criteria in patients with bone-only
metastatic breast cancer. Br J Cancer. 2010;102(4):
651–7.
6. Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura
N, Theriault RL, et al. A prospective study of bone
tumor response assessment in metastatic breast cancer.
Clin Breast Cancer. 2013;13(1):24–30.
7. Woolf DK, Padhani AR, Makris A.Assessing response
to treatment of bone metastases from breast cancer:
what should be the standard of care? Ann Oncol.
2015;26(6):1048–57.
8. Costelloe CM, Chuang HH, Madewell JE, Ueno
NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer.
2010;1:80–92.
9. Du Y, Cullum I, Illidge TM, Ell PJ.Fusion of metabolic function and morphology: sequential [18F]
uorodeoxyglucose positron-emission tomography/
computed tomography studies yield new insights into
the natural history of bone metastases in breast cancer.
J Clin Oncol. 2007;25(23):3440–7.
10. Min SJ, Jang HJ, Kim JH.Comparison of the RECIST
and PERCIST criteria in solid tumors: a pooled analysis and review. Oncotarget. 2016;7(19):27848–54.
11. Bauerle T, Merz M, Komljenovic D, Zwick S,
Semmler W.Drug-induced vessel remodeling in bone
metastases as assessed by dynamic contrast enhanced
magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res.
2010;16(12):3215–25.
12. Lecouvet FE, Larbi A, Pasoglou V, Omoumi P,
Tombal B, Michoux N, et al. MRI for response
assessment in metastatic bone disease. Eur Radiol.
2013;23(7):1986–97.
13. Chu S, Karimi S, Peck KK, Yamada Y, Lis E, Lyo
J, et al. Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced
magnetic resonance imaging: evaluation of tumor
response to radiation therapy. Spine (Phila Pa 1976).
2013;38(22):E1418–24.
14. Rose PS, Buchowski JM.Metastatic disease in the
thoracic and lumbar spine: evaluation and management. J Am Acad Orthop Surg. 2011;19(1):37–48.
15. Mukherjee S, Thakur B, Bhagawati D, Bhagawati D,
Akmal S, Arzoglou V, etal. Utility of routine biopsy
at vertebroplasty in the management of vertebral
compression fractures: a tertiary center experience. J
Neurosurg Spine. 2014;21(5):687–97.
16. Lis E, Bilsky MH, Pisinski L, Boland P, Healey
JH, O’Malley B, et al. Percutaneous CT-guided
biopsy of osseous lesion of the spine in patients with
known or suspected malignancy. Am J Neuroradiol.
2004;25(9):1583–8.
17. Singh VM, Salunga RC, Huang VJ, Tran Y, Erlander
M, Plumlee P, etal. Analysis of the effect of various
decalcication agents on the quantity and quality of
nucleic acid (DNA and RNA) recovered from bone
biopsies. Ann Diagn Pathol. 2013;17(4):322–6.

38
M. Vaynrub and J. H. Healey
18. Klimo P Jr, Schmidt MH.Surgical management of
spinal metastases. Oncologist. 2004;9(2):188–96.
19. Goldie JH, Coldman AJ. A mathematic model
for relating the drug sensitivity of tumors to their
spontaneous mutation rate. Cancer Treat Rep.
1979;63(11–12):1727–33.
20. Foo J, Michor F.Evolution of acquired resistance to
anti-cancer therapy. J Theor Biol. 2014;355:10–20.
21. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal
heterogeneity in cancer medicine. Br J Cancer.
2010;103(8):1139–43.
22. Dexter DL, Leith JT.Tumor heterogeneity and drug
resistance. J Clin Oncol. 1986;4(2):244–57.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the
next generation. Cell. 2011;144(5):646–74.
24. Mumenthaler SM, Foo J, Choi NC, Heise N, Leder
K, Agus DB, etal. The impact of microenvironmental
heterogeneity on the evolution of drug resistance in
cancer cells. Cancer Inform. 2015;14(Suppl 4):19–31.
25. Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro
E, Barile R, etal. Hormone receptor status and HER2
expression in primary breast cancer compared with
synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer. 2015;15(5):307–12.
26. Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A,
Rodon J, Tabernero J.The expanding role of immunotherapy. Cancer Treat Rev. 2017;54:74–86.
27. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W,
Buzdar A, etal. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann
Oncol. 2012;23(6):1378–86.
28. National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN
Guidelines(R)): breast cancer. Version 2.2016
(5/6/2016). Fort Washington: National Comprehensive
Cancer Network; 2016. https://www.nccn.org/profes-
sionals/physician_gls/pdf/breast.pdf.
29. Taghian A, El-Ghamry MN, Merajver SD.Overview
of the treatment of newly diagnosed, non-metastatic
breast cancer. UpToDate. NewYork: Wolters Kluwer;
10 Aug 2016. https://www.uptodate.com/contents/
overview-of-the-treatment-of-newly-diagnosed-nonmetastatic-breast-cancer. Accessed 5 Apr 2017.
30. Kim SR, Paik S. Genomics of adjuvant therapy for
breast cancer. Cancer J. 2011;17(6):500–4.
31. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran
A, Johnson RR, et al. Immunohistochemical surrogate markers of breast cancer molecular classes
predicts response to neoadjuvant chemotherapy: a
single institutional experience with 359 cases. Cancer.
2010;116(6):1431–9.
32. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT,
Collichio F, etal. The triple negative paradox: primary
tumor chemosensitivity of breast cancer subtypes.
Clin Cancer Res. 2007;13(8):2329–34.
33. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart
AA, Voskuil DW, etal. A gene-expression signature
as a predictor of survival in breast cancer. N Engl J
Med. 2002;347(25):1999–2009.
34. Gupta A, Mutebi M, Bardia A. Gene-expressionbased predictors for breast cancer. Ann Surg Oncol.
2015;22(11):3418–32.
35. Patsialou A, Wang Y, Lin J, Whitney K, Goswami S,
Kenny PA, etal. Selective gene-expression proling
of migratory tumor cells invivo predicts clinical outcome in breast cancer patients. Breast Cancer Res.
2012;14(5):R139.
36. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee
JM, Menke-Pluymers MB, Bartels CC, et al.
Sensitivity to rst-line chemotherapy for metastatic
breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(23):3764–71.
37. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J,
van Deurzen CH, etal. The efcacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2
mutation carriers. Cancer. 2012;118(4):899–907.
38. Smith KL, Isaacs C.BRCA mutation testing in determining breast cancer therapy. Cancer J. 2011;17(6):492–9.
39. Bayraktar S, Gluck S. Systemic therapy options in
BRCA mutation-associated breast cancer. Breast
Cancer Res Treat. 2012;135(2):355–66.
40. Pfeifer W, Sokolenko AP, Potapova ON, Bessonov
AA, Ivantsov AO, Laptiev SA, et al. Breast cancer
sensitivity to neoadjuvant therapy in BRCA1 and
CHEK2 mutation carriers and non-carriers. Breast
Cancer Res Treat. 2014;148(3):675–83.
41. Sholl LM.The molecular pathology of lung cancer.
Surg Pathol Clin. 2016;9(3):353–78.
42. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H,
Gabriel S, etal. EGFR mutations in lung cancer: correlation with clinical response to getinib therapy.
Science. 2004;304(5676):1497–500.
43. Korpanty GJ, Graham DM, Vincent MD, Leighl
NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and
KRAS.Front Oncol. 2014;4:204.
44. Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio
F, Dundar Y, et al. First-line treatment of advanced
epidermal growth factor receptor (EGFR) mutation
positive non-squamous non-small cell lung cancer.
Cochrane Database Syst Rev. 2016;(5):CD010383.
45. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K,
Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med.
2014;371(23):2167–77.
46. National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN
Guidelines(R)): prostate cancer. Version 2.2017
(02/21/17). Fort Washington: National Comprehensive
Cancer Network; 2017. https://www.nccn.org/profes-
sionals/physician_gls/pdf/prostate.pdf. Accessed 20
Mar 2017.
47. Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol.
2013;24(1):31–8.
48. Hellerstedt BA, Pienta KJ.The current state of hormonal therapy for prostate cancer. CA Cancer J Clin.
2002;52(3):154–79.

3 Relative Chemo-, Hormonal, and Immunosensitivity
39
49. Hurwitz ME, Sokhn J, Petrylak DP.Cancer immunotherapy: new applications in urologic oncology. Curr
Opin Urol. 2016;26(6):535–42.
50. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins
R, Guo J, et al. Pazopanib versus sunitinib in
metastatic renal-cell carcinoma. N Engl J Med.
2013;369(8):722–31.
51. McDermott DF, Cheng SC, Signoretti S, Margolin
KA, Clark JI, Sosman JA, etal. The high-dose aldesleukin “select” trial: a trial to prospectively validate
predictive models of response to treatment in patients
with metastatic renal cell carcinoma. Clin Cancer Res.
2015;21(3):561–8.
52. Motzer RJ, Escudier B, McDermott DF, George S,
Hammers HJ, Srinivas S, et al. Nivolumab versus
everolimus in advanced renal-cell carcinoma. N Engl
J Med. 2015;373(19):1803–13.
53. Messina C, Christie D, Zucca E, Gospodarowicz M,
Ferreri AJ.Primary and secondary bone lymphomas.
Cancer Treat Rev. 2015;41(3):235–46.
54. National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN
Guidelines (R)): B-cell lymphomas. Version 2.2017
(02/21/17). Fort Washington: National Comprehensive
Cancer Network; 2017. https://www.nccn.org/profes-
sionals/physician_gls/pdf/b-cell.pdf. Accessed 20
Mar 2017.
55. Pellegrini C, Gandol L, Quirini F, Ruggieri P, Stefoni
V, Derenzini E, etal. Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients. Clin Lymphoma Myeloma Leuk.
2011;11(4):321–5.
56. McDonald AC, Nicoll JA, Rampling RP. NonHodgkin’s lymphoma presenting with spinal cord
compression; a clinicopathological review of 25
cases. Eur J Cancer. 2000;36(2):207–13.
57. National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN
Guidelines(R)): multiple myeloma. Version 3.2017
(11/28/16). Fort Washington: National Comprehensive
Cancer Network; 2017. https://www.nccn.org/profes-
sionals/physician_gls/pdf/myeloma.pdf. Accessed 20
Mar 2017.
58. Ooi MG, de Mel S, Chng WJ. Risk stratication
in multiple myeloma. Curr Hematol Malig Rep.
2016;11(2):137–47.
59. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR,
Litzow MR, Henderson KJ, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and
-17p13 in myeloma patients treated with high-dose
therapy. Blood. 2005;106(8):2837–40.
60. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig
TE, Hayman SR, et al. Impact of risk stratication
on outcome among patients with multiple myeloma
receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114(3):518–21.
61. Durie BG, Jacobson J, Barlogie B, Crowley
J. Magnitude of response with myeloma frontline
therapy does not predict outcome: importance of time
to progression in southwest oncology group chemotherapy trials. J Clin Oncol. 2004;22(10):1857–63.
62. Schwab JH, Boland P, Guo T, Brennan MF, Singer S,
Healey JH, etal. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann
Surg Oncol. 2007;14(4):1507–14.
63. Moreau LC, Turcotte R, Ferguson P, Wunder J,
Clarkson P, Masri B, et al. Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol. 2012;19(4):
1081–8.
64. Schwab JH, Boland PJ, Antonescu C, Bilsky MH,
Healey JH. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance
imaging. Cancer. 2007;110(8):1815–22.
65. Kato S, Kawahara N, Murakami H, Demura S, Shirai
T, Tsuchiya H, et al. Multi-level total en bloc spondylectomy for solitary lumbar metastasis of myxoid
liposarcoma. Orthopedics. 2010;33(6):446.
66. Jones RL, Fisher C, Al-Muderis O, Judson
IR.Differential sensitivity of liposarcoma subtypes to
chemotherapy. Eur J Cancer. 2005;41(18):2853–60.
67. Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto
T, Takahashi M, et al. Trabectedin monotherapy
after standard chemotherapy versus best supportive
care in patients with advanced, translocation-related
sarcoma: a randomised, open-label, phase 2 study.
Lancet Oncol. 2015;16(4):406–16.
68. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack
G, Adams JE, etal. Effect of an aromatase inhibitor
on bmd and bone turnover markers: 2-year results of
the Anastrozole, Tamoxifen, Alone or in Combination
(ATAC) trial (18233230). J Bone Miner Res.
2006;21(8):1215–23.
69. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier
RM, Tavernier C. Bone mineral density in men
treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol.
1999;161(4):1219–22.
70. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon
KH, et al. The effect of bone marrow transplantation on the osteoblastic differentiation of human
bone marrow stromal cells. J Clin Endocrinol Metab.
2002;87(1):329–35.
71. Shapiro CL, Manola J, Leboff M.Ovarian failure after
adjuvant chemotherapy is associated with rapid bone
loss in women with early-stage breast cancer. J Clin
Oncol. 2001;19(14):3306–11.
72. Gnant M, Mlineritsch B, Luschin-Ebengreuth G,
Kainberger F, Kassmann H, Piswanger-Solkner JC,
et al. Adjuvant endocrine therapy plus zoledronic
acid in premenopausal women with early-stage breast
cancer: 5-year follow-up of the ABCSG-12 bonemineral density substudy. Lancet Oncol. 2008;9(9):
840–9.
73. Gralow JR, Biermann JS, Farooki A, Fornier MN,
Gagel RF, Kumar R, etal. NCCN Task Force Report:
bone health in cancer care. J Natl Compr Canc Netw.
2013;11(Suppl 3):S1–50; quiz S1.

40
M. Vaynrub and J. H. Healey
74. Kanis JA. Determinants of skeletal mass and strength
[chapter 4]; causes of osteoporosis [chapter 5]. In:
Kanis JA, editor. Textbook of osteoporosis. Oxford
and Cambridge: Blackwell Science; 1996. p. 106–99.
75. Vehmanen L, Elomaa I, Blomqvist C, Saarto
T.Tamoxifen treatment after adjuvant chemotherapy
has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J
Clin Oncol. 2006;24(4):675–80.
76. Prolia(R) (denosumab) Injection [package insert].
Thousand Oaks: Amgen Inc.; 2011. https://
www.accessdata.fda.gov/drugsatfda_docs/
label/2011/125320s5s6lbl.pdf.
77. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora
S, Smith J, et al. Randomized trial of denosumab
in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol.
2008;26(30):4875–82.
78. Van Poznak C, Hannon RA, Mackey JR, Campone M,
Apffelstaedt JP, Clack G, etal. Prevention of aromatase inhibitor-induced bone loss using risedronate: the
SABRE trial. J Clin Oncol. 2010;28(6):967–75.
79. Canalis E, Giustina A, Bilezikian JP.Mechanisms of
anabolic therapies for osteoporosis. N Engl J Med.
2007;357(9):905–16.
80. Wong MH, Stockler MR, Pavlakis N.Bisphosphonates
and other bone agents for breast cancer. Cochrane
Database Syst Rev. 2012;(2):CD003474.
81. Lipton A.Efcacy and safety of intravenous bisphosphonates in patients with bone metastases caused
by metastatic breast cancer. Clin Breast Cancer.
2007;7(Suppl 1):S14–20.
82. ZOMETA(R) (zoledronic acid) Injection [package insert]. East Hanover: Novartis Pharmaceuticals
Corporation; 2014. https://www.accessdata.fda.gov/
drugsatfda_docs/label/2014/021223s028lbl.pdf.
83. XGEVA(R) (denosumab) Injection [package insert].
Thousand Oaks: Amgen Inc.; 2013. https://www.
accessdata.fda.gov/drugsatfda_docs/label/2013/
125320s094lbl.pdf.
84. Fizazi K, Carducci M, Smith M, Damiao R, Brown J,
Karsh L, etal. Denosumab versus zoledronic acid for
treatment of bone metastases in men with castrationresistant prostate cancer: a randomised, double-blind
study. Lancet. 2011;377(9768):813–22.
85. Martin M, Bell R, Bourgeois H, Brufsky A, Diel I,
Eniu A, etal. Bone-related complications and quality of life in advanced breast cancer: results from
a randomized phase III trial of denosumab versus
zoledronic acid. Clin Cancer Res. 2012;18(17):
4841–9.
86. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria
V, Prausova J, etal. Randomized, double-blind study
of denosumab versus zoledronic acid in the treatment
of bone metastases in patients with advanced cancer
(excluding breast and prostate cancer) or multiple
myeloma. J Clin Oncol. 2011;29(9):1125–32.
87. Ben-Aharon I, Vidal L, Rizel S, Yerushalmi R,
Shpilberg O, Sulkes A, et al. Bisphosphonates in the
adjuvant setting of breast cancer therapy—effect on
survival: a systematic review and meta-analysis. PLoS
One. 2013;8(8):e70044.

NOMS
ScottL.Zuckerman, IlyaLaufer, andMarkBilsky
4
The spine is the most common site of bony
metastases in patients with cancer [1, 2]. Spinal
metastases occur in 30–50% of patients, and
common primary cancers known to metastasize
to the spine include breast, prostate, renal, and
lung [3, 4]. Through tumor spread from the arterial system, epidural venous plexus, cerebrospinal uid (CSF), or direct extension, symptoms
develop secondary to painful vertebral body
involvement or neurologic compromise from
metastatic epidural spinal cord compression
(ESCC) [5]. Improved treatment has led to an
increase in the incidence and prevalence of
patients both living with metastatic spine disease
and undergoing therapy for these tumors [6–8].
Patients with spinal metastases are medically
complex. Deconditioned and malnourished, they
have often undergone or are actively receiving
chemotherapy and/or radiation. These factors
require consideration when pursuing surgical
intervention. Major treatment decisions are often
made in conjunction with a team of oncologic
providers. As cancer treatments rapidly evolve,
so does the role of the spine surgeon. Operative
treatments have progressed from simple stabili-
zation [9] to invasive resections [10] to separation surgery [11, 12]. The spine surgeon must
now be aware of both minimally invasive surgical
(MIS) techniques in addition to novel radiosurgical options.
The NOMS framework consists of four sentinel considerations used to guide choice of therapy for patients with spinal metastases. The
NOMS decision points include neurologic, oncologic, mechanical, and systemic considerations
and provide a dynamic framework that may
incorporate novel therapies. Herein we describe
the NOMS framework with a special emphasis
on the role of the surgeon. Notable concepts are
subsequently discussed in addition to challenging
case presentations.
NOMS Framework
The NOMS algorithm utilizes four decision
points of assessment in order to determine the
optimal combination of systemic therapy, radiation and surgery (Fig.4.1).
S. L. Zuckerman, MD, MPH
Department of Neurological Surgery, Vanderbilt
University Medical Center, Nashville, TN, USA
e-mail: scott.zuckerman@vanderbilt.edu
I. Laufer, MD · M. Bilsky, MD (*)
Department of Neurosurgery, Memorial Sloan
Kettering Cancer Center, New York, NY, USA
e-mail: lauferi@mskcc.org; bilskym@mskcc.org
© Springer International Publishing AG, part of Springer Nature 2018
R. A. W. Marco (ed.), Metastatic Spine Disease, https://doi.org/10.1007/978-3-319-76252-4_4
Neurologic
The neurologic assessment includes a neurologic
examination and determination of ESCC severity. ESCC is a radiologic evaluation and dichotomized to low or high grade, whereas myelopathy
is determined through physical exam and also
41

42
Systemic
Low-grade ESCC
No myelopathy
S. L. Zuckerman et al.
Radiation
High-grade ESCC
+/- myelopathy
NeurologicOncologicMechanical
cEBRT
SRS
Radiosensitive
Radioresistant/
previously radiated
Separation surgery
Stable
Unstable
Able to tolerate
surgery
Unable to tolerate
surgery
Fig. 4.1 NOMS framework. From Laufer et al., The NOMS Framework: Approach to the Treatment of Spinal
Metastatic Tumors. Oncologist. 2013 Jun;18(6):744–51. doi: 10.1634/theoncologist.2012-0293. Epub 2013 May 24
Stabilization
dichotomized into presence or absence of neurologic decit (myelopathy or radiculopathy). It is
of paramount importance that the neurologic
evaluation is standardized; care becomes fractured if medical and surgical teams cannot communicate, and meaningful treatment decisions
cannot be made. We cannot overemphasize the
importance of the neurologic exam.
The examining physician should rst take a
thorough history, taking note of specic symptoms (dropping things, trouble buttoning shirt,
difculty with utensils or counting change, gait
imbalance, or bowel/bladder dysfunction) and
signs (hyperreexia, clonus, decreased rectal
tone, or a positive Hoffman, Babinski, Romberg,
Spurling’s, or Lhermitte’s sign). Motor or sensory
decits can be determined by one of the several
commonly used grading scales. The American
Spinal Injury Association (ASIA) classication
is commonly used, ranging from neurologically
intact (E) to a complete injury (A) [13], which is
a modication of the Frankel scale. The Nurick
and Ranawat scales are older and slightly more
complex but can still be used to quantify the
level of dysfunction. Myelopathy-specic scales
include the McCormick scale [14] that assesses
motor, sensory, and gait, originally developed for
intradural tumors, or the Aminoff-Logue scale
[15] for gait and micturition, originally developed for spinal arteriovenous malformations.
Radiologic ESCC is best evaluated by a sixpoint grading scale [16] that was developed
from a previous four-point grading scale [17].
The six- point grading scale describes bone-only
disease (0), epidural impingement without
deformation of the thecal sac (1a), deformation
of the thecal sac without spinal cord abutment
(1b), deformation of the thecal sac with spinal
cord abutment (1c), spinal cord compression
with CSF visible (2), and spinal cord compression without CSF visible (3) (Fig. 4.2). In a
study of seven spine surgeons, 25 MRI scans of

4 NOMS
abc
0
Fig. 4.2 (a–c) ESCC scale. From Bilsky etal., Reliability Analysis of the Epidural Spinal Cord Compression
Scale. Journal of Neurosurgery: Spine. 2010 Sep; 13(3):324–328
1c
1b
1a
2
43
3
cervical and thoracic tumors were shown three
times at 2-week intervals, and the T2-weighted
images produced good to excellent inter-rater
(ICC 0.701–0.782) and intra-rater (ICC 0.619–
0.819) reliability, which was signicantly superior to T1-weighted images [16]. The NOMS
framework considers Grades 0 and 1a–c low
grade and Grades 2 and 3 high grade.
Armed with a reliable neurologic and ESCC
assessment, low-grade ESCC is universally considered for radiation treatment in the absence of
any mechanical instability, regardless of radiosensitivity. For high-grade ESCC with or without
neurologic decit (Grades 2 and 3), separation
surgery is offered unless the tumor is radiosensitive, in which case radiation is pursued. As previously stated, the role of 1c ESCC remains ill
dened and depends on the patient’s neurologic
status. If there is a signicant neurologic decit
due to tumor abutment and/or inammation, surgery may be more suitable. However, if the
patient is neurologically intact, a hypofractionated radiation regimen may provide desired
response while avoiding surgery.
Within the scope of the neurologic assessment, the time and severity of a neurologic
decit are of paramount importance. Most
often in the emergency department, but sometimes encountered during a clinic visit, the
acuity and severity of neurologic decit deterioration must be determined quickly. In the
setting of spinal cord compression by solid
tumor resulting in neurologic decit, surgery
provides the most rapid and reliable decompression of the spinal cord. Laufer etal. [18]
conducted a systematic review to outline what
preoperative indicators were associated with
neurologic improvement after surgery, and
both duration of symptoms and severity of deficit were consistently found to predict outcome. Five articles endorsed an association
between duration of symptom onset and severity of symptoms that was discussed in two
studies. These two factors were the most powerful inuences of neurologic recovery.
The same authors administered a survey to 32
members of the AOSpine Knowledge Forum
Tumor group (94% surgeons, 6% radiation
oncologists) with a median practice duration of
8years (range 1–38) [18]. A satisfactory surgical
outcome was dened as motor improvement
(69%) or preservation of bowel/bladder function
without ambulation (90%). Agreement was
unanimous that duration of ambulation loss
should be considered when deciding on surgery.
Forty-one percent responded that surgery could
be pursued in the case of prolonged duration of
ambulation loss. In terms of specic timing, 13%
excluded surgery at >24h of ambulation loss,
and 69% stated patients were less likely to
recover at 48h of ambulation loss. In terms of
severity of weakness, 94% believed this was an
important variable. Forty percent stated 0/5
lower extremity strength excluded patients from
surgery, and 23% used their surgical cut-off at
1/5 strength.

44
S. L. Zuckerman et al.
Oncologic
The oncologic assessment considers the responsiveness of a tumor to available treatments. For
the most part, this is determined by the effect of
radiation. Radiation is the least invasive and most
successful option for local tumor control.
However, increasing success is being seen with
chemotherapy and immunotherapy options.
Thus, the oncologic perspective is determined
mostly by radiosensitivity of the primary tumor
but can be further modied by effective chemotherapy and/or immunotherapy options.
Radiation
Currently the main methods of radiation delivery
include cEBRT and SRS. cEBRT delivers two
opposing radiation beams to a fairly large region
using additive low-dose fractions. Ten fractions
of 3Gy to a total dose of 30 Gy represent the
most commonly utilized cEBRT dosing in the
spine. Advances in radiation technology have
allowed delivery of radiation in highly focused
and conformal manner using image guidance.
This form of radiation therapy, known as stereotactic radiosurgery (SRS), allows delivery of
high-dose radiation to tumors while sparing the
surrounding organs at risk (OAR).
Radiosensitive. A recent review of the literature shows that different tumor histology
dictates responsiveness to cEBRT (Table 4.1).
Universally, lymphoma, seminoma, and myeloma
are radiosensitive. It makes intuitive sense that the
nonsolid tumors rarely require surgery and have
an excellent response to radiation. Among solid
tumors, breast and prostate are also categorized
as radiosensitive. In 1995, Maranzano and Latini
[20] conducted a prospective trial and reported
that when diagnosed early or late, radiosensitive histologies (myeloma, breast, prostate) were
associated with higher median response times
and improved survival. The more recent literature agrees with these early results. Rades and
colleagues [21] retrospectively analyzed 238
patients with ESCC secondary to myeloma and
found that cEBRT alone led to a positive response
in 97%—motor improvement in 53% and stable
motor decit in 44%. The same group treated 29
patients with lymphoma causing ESCC and found
that 72% improved motor function and 28% were
stable with cEBRT alone [22]. Similarly favorable results were reported in four young men
with seminomas [23]. Tumors with radiosensitive histology also respond signicantly better
to increased doses of radiation, even when doses
extend beyond 30Gy [24]. Breast and prostate
cancers are also radiosensitive but less so than the
nonsolid tumors. The NOMS framework states
that for radiosensitive tumors, even with highgrade ESCC, cEBRT can be used for local tumor
control [25]. However, in cases of symptomatic
spinal cord compression, especially by solid
radiosensitive malignancies, surgery still plays an
important role.
Radioresistant. Many solid tumors on the
other hand are quite radioresistant. Renal cell
carcinoma (RCC), gastrointestinal (GI), and
non- small cell lung cancer (NSCLC) are
encountered often and less responsive to
cEBRT. SRS employs tumor kill pathways that
are different from cEBRT and therefore overcomes radioresistance to cEBRT.Radioresistant
Table 4.1 Response to radiation based on histology [19]
Lymphoma
Seminoma
Myeloma Breast Prostate Sarcoma Melanoma GI NSCLC Renal
Gilbert F F U U U U U U
Maranzano F F F U U U U U
Rades F I I I U I U I
Rades F F F U U U U U
Katagiri F F F U U U U U
Maranzano F F F U U U U U
Rades F I I I U I U I
Responses: F favorable, I intermediate, U unfavorable
Соседние файлы в папке Библиотека им академика М.И. Перельмана
